1.23 USD
-0.02 (-1.6%)
1.22 USD
-0.01 (-0.81%)
We assign a fundamental rating of 4 out of 10 to SBFM. SBFM was compared to 525 industry peers in the Biotechnology industry. The financial health of SBFM is average, but there are quite some concerns on its profitability. SBFM is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- SBFM had negative earnings in the past year.
- SBFM had a negative operating cash flow in the past year.
- In the past 5 years SBFM always reported negative net income.
- SBFM had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of -19.03%, SBFM is in the better half of the industry, outperforming 77.14% of the companies in the same industry.
- Looking at the Return On Equity, with a value of -24.76%, SBFM is in the better half of the industry, outperforming 79.81% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -19.03% | ||
| ROE | -24.76% | ||
| ROIC | N/A |
ROA(3y)-41.58%
ROA(5y)-191.13%
ROE(3y)-55.58%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- SBFM has a Gross Margin of 33.01%. This is in the better half of the industry: SBFM outperforms 73.33% of its industry peers.
- In the last couple of years the Gross Margin of SBFM has declined.
- The Profit Margin and Operating Margin are not available for SBFM so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 33.01% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.34%
GM growth 5Y-8.47%
2. Health
2.1 Basic Checks
- SBFM does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, SBFM has more shares outstanding
- SBFM has more shares outstanding than it did 5 years ago.
- SBFM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- Based on the Altman-Z score of -1.25, we must say that SBFM is in the distress zone and has some risk of bankruptcy.
- SBFM has a Altman-Z score (-1.25) which is in line with its industry peers.
- There is no outstanding debt for SBFM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.25 |
ROIC/WACCN/A
WACC8.88%
2.3 Liquidity
- SBFM has a Current Ratio of 4.20. This indicates that SBFM is financially healthy and has no problem in meeting its short term obligations.
- SBFM has a Current ratio of 4.20. This is comparable to the rest of the industry: SBFM outperforms 50.10% of its industry peers.
- A Quick Ratio of 2.09 indicates that SBFM has no problem at all paying its short term obligations.
- The Quick ratio of SBFM (2.09) is worse than 73.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.2 | ||
| Quick Ratio | 2.09 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 88.82% over the past year.
- SBFM shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 13.24%.
- The Revenue has been growing by 340.61% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)88.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.79%
Revenue 1Y (TTM)13.24%
Revenue growth 3Y434.8%
Revenue growth 5Y340.61%
Sales Q2Q%11.64%
3.2 Future
- Based on estimates for the next years, SBFM will show a very strong growth in Earnings Per Share. The EPS will grow by 41.20% on average per year.
- The Revenue is expected to grow by 15.04% on average over the next years. This is quite good.
EPS Next Y98.01%
EPS Next 2Y41.2%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-0.21%
Revenue Next 2Y15.04%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
- SBFM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SBFM. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as SBFM's earnings are expected to grow with 41.20% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.2%
EPS Next 3YN/A
5. Dividend
5.1 Amount
- SBFM does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
SUNSHINE BIOPHARMA INC / SBFM FAQ
Can you provide the ChartMill fundamental rating for SUNSHINE BIOPHARMA INC?
ChartMill assigns a fundamental rating of 4 / 10 to SBFM.
Can you provide the valuation status for SUNSHINE BIOPHARMA INC?
ChartMill assigns a valuation rating of 1 / 10 to SUNSHINE BIOPHARMA INC (SBFM). This can be considered as Overvalued.
How profitable is SUNSHINE BIOPHARMA INC (SBFM) stock?
SUNSHINE BIOPHARMA INC (SBFM) has a profitability rating of 2 / 10.